Heart Failure

  • Nages Nagaratnam
  • Kujan Nagaratnam
  • Gary Cheuk
Reference work entry

Abstract

This chapter provides an overview of heart failure, prevalence and mechanisms followed by an update on the clinical management. The prevalence heart failure is likely to increase over the next few decades with the increase in world population and in over 65 years. With increasing age, there are alterations in structure and function of the heart and vasculature which may eventually affect the cardiovascular performance. Age is the most important factor in cardiovascular risk scores. Heart failure is largely a disease of the elderly and is the major cause of disability in the elderly. The elderly are inclined to developing heart failure as a result of age-related changes in the cardiovascular system and high prevalence of coronary heart disease and hypertension. Older patients could present with confusion, sleeplessness, agitation, depression, loss of appetite or nausea, weakness, cough and breathlessness on exertion. The management of heart failure is dictated by the mechanism underlying the heart failure. Patients with systolic heart failure had higher death rates than patients with diastolic heart failure although the death rates in the latter group were still much higher than those without heart failure. There have been considerable advances in the treatment of heart failure, yet the mortality remains high at 50% after 5 years. The case for heart failure prevention is very strong. The impact of heart failure will significantly increase with the population ageing and poses a heavy burden on the healthcare system.

Keywords

Heart failure Systolic heart failure Diastolic heart failure Impact of heart failure B-type natriuretic peptide (BNP) Cardiovascular ageing 

References

  1. 1.
    Centers for DIsease Control and Prevention. Trends in aging-United States and world-wide. MMWR Morb Mortal Wkly Rep. 2003;52:101–4.Google Scholar
  2. 2.
    Wald NJ, Law MR. A strategy to reduce cardiovascular diseases by more than 80%. BMJ 2003;326:1419–23.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Wood DA, Wray R, Poulter N, Williams B, Kirbig M, Patel V. JBS2: Joint British Societies guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;92 (suppl 5)V1–52.Google Scholar
  4. 4.
    Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity mortality and cost. Clin Geriatr Med 2009; 25(4):563-vii.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    World Health Organisation. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. WHO Press, 2007.Google Scholar
  6. 6.
    Priebe HJ. The aged cardiovascular risk patient. Br J Anaesth 2000; 85(5):763–78.CrossRefPubMedGoogle Scholar
  7. 7.
    Pugh KG, Wei JV. Clinical implications of physiological changes in the aging heart. Drugs Aging 2001;18(4): 263–76.CrossRefPubMedGoogle Scholar
  8. 8.
    Strait JB, Lakatta EG. Age-associated cardiovascular changes and their relationship to heart failure. Heart Fail Clin. 2012; 8(1):143–164.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kumar A, Meyerosse G, Sood V, Roongsritong C. Diastolic heart failure in the elderly and the potential role of aldosterone antagonists. Drugs Aging 2006;23(4):299–308.CrossRefPubMedGoogle Scholar
  10. 10.
    Gottdiener JS, McClelland RL, Marshall R, Shamanski L, Fulberg CD, Kitzman DW, et al. Heart failure in the elderly. Ann Int Med 2002;137:631–639.CrossRefPubMedGoogle Scholar
  11. 11.
    Sharpe N Heart failure in the community. Prog Cardiovasc Dis 1998;41(1):73–76.CrossRefPubMedGoogle Scholar
  12. 12.
    Luche RJ, Taffet GE,Tearsdale TA. Congestive heart failure in the elderly. J Am Geriatr Soc 1991;39:810.CrossRefGoogle Scholar
  13. 13.
    Roger VL, Weston SA, Redfield MM, Hellrman-Homan JP, Killian J, Yawn BD, Trends in heart failure incidence and survival in a community-based population. JAMA 2004;292(3):344–50.CrossRefPubMedGoogle Scholar
  14. 14.
    Jugditt BI . Aging and heart failure: Mechanisms and Management. Am J Geriatr Soc 1997;45:968–74.CrossRefGoogle Scholar
  15. 15.
    Owan TE, Hodge DU, Hherges RM, Jacobsen ST, Roger IL, Redfield MM. Trends in prevalence and outcome of heart failure with pressed ejection fraction . NEJM 2006;355:251–9CrossRefPubMedGoogle Scholar
  16. 16.
    Schocken DD. Epidemiology and risk factors of heart failure in the elderly. Clin Geriatr Med 2000;16(2):407–18.CrossRefPubMedGoogle Scholar
  17. 17.
    Murphy NF, Simpson CR, McAlister FA, Stewart S, MacIntyre K, Kirkpatrick M, et al. National Survey of prevalence, incidence, primary care burden and treatment of heart failure in Scotland. Heart 2004;90:1129–1136.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Berterri AG, Hundley WG, Massing MW, Bonds DE, Burke L, Goff DC Jr, et al. Heart failure prevalence, incidence and mortality in the elderly with diabetes. Diabetes Care 2004;27(3):699–703.CrossRefGoogle Scholar
  19. 19.
    American Heart Association 2002. Heart and Stroke Update. Dallas. American Heart Association. 2002.Google Scholar
  20. 20.
    Burlew BS. Diastolic dysfunction in the elderly-the interstitial tissue. Am J Geriatr Cardiol 2004;13(1):29–38.CrossRefPubMedGoogle Scholar
  21. 21.
    Kitzman JM, Gardin JM, Gottdiener JS, Arnold AM, Boineau R, Aurigemma G, et al. Importance of heart failure with preserved systolic function in patients >65 years of age. Am J Cardiol 2001;344:413–419.CrossRefGoogle Scholar
  22. 22.
    Zili MR, Britsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part I diagnosis, prognosis and measurements of diastolic function. Circulation 2002;105:1387–93.CrossRefGoogle Scholar
  23. 23.
    Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002;288:2144–50.CrossRefPubMedGoogle Scholar
  24. 24.
    Johnson M. Heart starter. Pathway. http://pathway.rcpa.edu.au Circulation 2002;106:416–22
  25. 25.
    Davies AP, Francis CM, Love MP, Caruana L, Starkey IR, Shaw TR, et al. Value of electrocardiogram in identifying heart failure due to left systolic dysfunction. BMJ 1996;312:232.Google Scholar
  26. 26.
    Ewald B, Ewald D,Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Int Med J 2008;38:101–113.CrossRefGoogle Scholar
  27. 27.
    Angermann CE,Ertl G. Natriuretic peptides-new diagnostic markers in heart disease. Herz 2004;29(6):5609–17.CrossRefGoogle Scholar
  28. 28.
    Mueller C, Scholer A, Laule-Kilia K, Martina B, Schindler C, Buse P, et al. Use of B-type natriuretic peptide in the evaluation and management of dyspnoea. NEJM 2004;350:647–654.CrossRefPubMedGoogle Scholar
  29. 29.
    Chew DPB, Scott IA. The changing face of cardiovascular care in Australia. MJA. 198(11):604605).Google Scholar
  30. 30.
    Rich MW. Heart failure in the 21st century: a cardiogeriatric syndrome. J Gerontol A Biol Med Sci 2001;56(2):M88–96.CrossRefGoogle Scholar
  31. 31.
    The American College of Cardiology and American Heart Association (ACC/AHA) 200. Guidelines Update.Google Scholar
  32. 32.
    National Vascular Disease Alliance .Guidelines for the management of absolute cardiovascular disease risk. Melbourne National Stroke Foundation, 2012. As quoted by Nelson and Doust, 2013.Google Scholar
  33. 33.
    National Vascular Disease Preventing Alliance. Guidelines for the assessment of absolute cardiovascular disease risk. Melbourne: National Stroke Foundation, 2009 as quoted by Nelson and Doust, 2013.Google Scholar
  34. 34.
    Nelson MR, Doust JA. Primary prevention of cardiovascular disease: new guidelines techniques and therapies. MJA. 2013;198(11):606–610.PubMedGoogle Scholar
  35. 35.
    Vasan RS, Benjamin EJ Diastolic heart failure-no time to relax. Editorial. New Engl J Med 2001;344:56–59.Google Scholar
  36. 36.
    Flather MD, Shibata MC, Coats AJS, Van Veldhnisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J, 2005;26(3):215–225.CrossRefPubMedGoogle Scholar
  37. 37.
    Jones EF. Drug therapy of heart failure in the elderly. Aus J Hosp Pharmacy 2000;30:274–278.CrossRefGoogle Scholar
  38. 38.
    Mandinov L, Eberli FR, Seiler C, Hess OM. Diastolic heart failure. Cardiovasc Res 2000;45:813–25.CrossRefPubMedGoogle Scholar
  39. 39.
    Yusuf S, Pfeiffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effect of candesartan in patients with congestive heart failure and preserved left ventricle ejection fraction. The CHARM-Preserved Trial. Lancet 2003;362:777–81.CrossRefPubMedGoogle Scholar
  40. 40.
    Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005;112:357–363.CrossRefPubMedGoogle Scholar
  41. 41.
    Klabunde RE. The Pathophysiology of heart failure. http://cvpharmacology.com/clinical%20topics/heart%20failure-3.htm accessed 19/4/13.
  42. 42.
    Mazaffarian D, Nye R, Levy WC. Statin therapy among patients with severe heart failure. Am J Cardiol 2004;93:1124–9.CrossRefGoogle Scholar
  43. 43.
    Howard PA, Cheng JW, Cronel MA. Drug therapies recommendations from the 2005 ACC/AHA guidelines for treatment of chronic heart failure. Ann Pharmacother. 2006;40:1607–17.CrossRefPubMedGoogle Scholar
  44. 44.
    Werner N, Bohan M. ACE inhibitor in the elderly. Is there evidence for a life long blockade of the renin-angiotensin-systems? Eur Soc Cardiol. 2004;2(41): http://www.escardio.org/co.
  45. 45.
    Garg R,Yusuf S. Over view of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group om ACE inhibitor Trials. JAMA 1995;273:1450–56.CrossRefPubMedGoogle Scholar
  46. 46.
    Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429–35.CrossRefGoogle Scholar
  47. 47.
    Sweitzer NK. What is an angiotensin converting co-enzyme inhibitor. Circulation. 2003;108:816–818.CrossRefGoogle Scholar
  48. 48.
    Weber KT, Brilla CG, Campbell SE, Zhou G, Matsubara L, Guarda E Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press. 1992;1(2):75–85.CrossRefPubMedGoogle Scholar
  49. 49.
    Linfield J, Albut NM, Boehmer JP, Collins SP, Ezckowitz JA, Givertz MM, et al. Executive survey HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Cardiol Fail. 2010; 16:475–539.CrossRefGoogle Scholar
  50. 50.
    McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effect of candesartan with chronic heart failure and reduce left ventricular systolic function taking angiotensin –converting enzyme inhibitors. The CHARM –Added trial. Lancet. 2003;362:767–771.CrossRefPubMedGoogle Scholar
  51. 51.
    Lee S, Spencer A. Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis. J Farm Pract. 2001;50:499–504.Google Scholar
  52. 52.
    Packer M,Coats AJ, Fowler MB, Katus HA, Krum H, Mohaesi P, et al. for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.Google Scholar
  53. 53.
    Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium sparing diuretics. J Clin Hypertens (Greenwich). 2011;13(9):644–8.CrossRefGoogle Scholar
  54. 54.
    Isakadze A, Makharadze T, Gvishiani M. The efficacy of ivabradine in chronic heart failyre (review). Georgian Med News. 2015;241:44–9.Google Scholar
  55. 55.
    Swedberg K, Kamagda M, Bohm M, Borer J, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo – controlled study. The Lancet. 2010;376(9744):875–888.CrossRefGoogle Scholar
  56. 56.
    NPS Medicine wise, RADAR August. 2014. www.nps.org.au/radar/artiles/ivabradine-corsalan-for-chronic-heart-failutre. accessed 25 June 2016.
  57. 57.
    Muller-Werdan U, Stock G, Ebelt H, Nuding S, Hopfner F, Werdan K, et al. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study. Exp Gerontol. 2014;59:34–41.CrossRefPubMedGoogle Scholar
  58. 58.
    Anonymous –New medicines: Procoralan. Phramacetical J. 2006;276(7386):13–15.Google Scholar
  59. 59.
    Liu SS, Monti J, Kargbo HM, Ather MW, Parakh K. Frontiers of therapy for patients with heart failure. Am J Med. 2013;126:6–12.CrossRefPubMedGoogle Scholar
  60. 60.
    Digoxin Investigating Group . The effect of digoxin on mortality and morbidity in patients with heart failure. NEJM. 1997;336(8):525–532.CrossRefGoogle Scholar
  61. 61.
    Cayley WE Jr. Digoxin in chronic heart failure. Family Practice 2004;21(4):469–472.CrossRefPubMedGoogle Scholar
  62. 62.
    Cohn JN, Johnson G, Ziesche S, Cobb F,Francis G, Tristani F, et al. A comparison of enalapril with hydralazine+ isosorbide dinitrate in the treatment of chronic congestive heart failure. NEJM. 1991;325:303–310.CrossRefPubMedGoogle Scholar
  63. 63.
    ACC/AHA Pocket Guidelines, 2005.Google Scholar
  64. 64.
    Schwinger RHC, Erdmann E. Heart failure and electrolyte disturbances. Methods and findings in experimental and clinical pharmacology. 1992;14:315–325.PubMedGoogle Scholar
  65. 65.
    Lane RE, Cowle HR, Chew AWC. Prediction and prevention of sudden cardiac death in heart failure. Heart. 2005;91:674–680.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Kerwin WF, Botrinick EH, O’Connell JW, Merrick SH, DeMarco T, Chatterjee K, et al. Ventricular contraction abnormalities in dilated cardiomyopathies: effect of biventricular pacing to correct interventricular dyssynchrony. J Am Coll Cardiol. 2000;35:1221–7.CrossRefPubMedGoogle Scholar
  67. 67.
    Cazecui S, Leclercq C, Lavargne T,Walker S, Varma C, Linde C, et al. Effect of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay . NEJM. 2001;344:873–80.CrossRefGoogle Scholar
  68. 68.
    Abraham WF, Fisher WG, Smith DC, DeLurgo DB, Leon AR, Loh E, et al. Cardiac synchronization in congestive heart failure. NEJM. 2002;346;1845–53.CrossRefPubMedGoogle Scholar
  69. 69.
    Murad K, Kitzman DW. Frailty and multiple comorbidities in the elderly patient with heart failure: implications and management. Heart Fail Rev. 2012;17(0):581–5.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Cafagna D, Pone E, Burri R. The concept of quality of life in cardiac failure. Minerva Med 1997;8(4):151–62.Google Scholar
  71. 71.
    Heidenreich PA, Albert CN, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States. Circulation: Heart Failure. 2013.  https://doi.org/10.1161/HHF.0bo13e318291329a.
  72. 72.
    Hobbs FD, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J. 2002;23(23):167–76.CrossRefGoogle Scholar
  73. 73.
    Opasich C, Guaico A, De Feo S, Barbieri M, Cloffi G, Giardini A, et al. Physical and emotional symptom burden of patients with end-stage heart failure: what to measure and how and why? J Cardiolvasc Med (Hagerstown). 2008;9(11):1104–8.CrossRefGoogle Scholar
  74. 74.
    Bekelman DB, Havravek EP, Beker DM, Kutner JS, Peterson PN, Wittstein IS, et al. Symptom depression and quality of life in patients with heart failure. J Cardiol Fail. 2007;13(8):643–8.CrossRefGoogle Scholar
  75. 75.
    Herrero-Puente P, Manno-Genicio R, Martn-Sanchez FJ, Vazquez-Alvarez J, Jacob J, Bermudez M. Characteristics of heart failure in very elderly patients-EVE study (EAHFE very elderly) Eur J Int Med.  https://doi.org/10.1016/ajm.2014.04.002.
  76. 76.
    Liao L, Anstrom KJ, Gottdiener JS, Pappos PA, Whellen DJ, Kitzman DW,et al. Long term costs, resource use in elderly patients with congestive heart failure in the Cardiovascular Heart Study. Am Heart J. 2007;153:245–252.CrossRefPubMedGoogle Scholar
  77. 77.
    Selman L, Beynon, Higginta LJ, Harding R. Psychological, social and spiritual distress at the end of life in heart failure patients. Curr Opin. Support Palliative Care. 2007;1(4):260–6.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Nages Nagaratnam
    • 1
  • Kujan Nagaratnam
    • 1
  • Gary Cheuk
    • 2
  1. 1.The University of SydneyWestmead Clinical SchoolWestmeadAustralia
  2. 2.Rehabilitation and Aged Care ServiceBlacktown-Mt Druitt HospitalMount DruittAustralia

Personalised recommendations